Chemical structure of fluvastatin
Find information on thousands of medical conditions and prescription drugs.

Fluvastatin

Fluvastatin (Lescol®, Canef®) is a member of the drug class of statins, used to treat hypercholesterolemia and to prevent cardiovascular disease.


Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Statins on equal footing in MI patients
From Geriatrics, 7/1/05

Five statins have been found to be equally effective for secondary prevention of acute MI in older patients.

"We are not surprised by the findings, despite claims for certain statins being 'better' than others," says lead author Frank Z. Zhou, MD, of McGill University, Montreal. "At regular prescribed doses, we found that choice of statin does not make a difference in preventing recurrent AMI or death."

In this 5-year retrospective cohort study, Dr. Zhou et al compared 5 statins using data from medical administrative databases in 3 provinces (Quebec, Ontario, and British Columbia). Participants (age 65 and older) were discharged alive after their first AMI-related hospital stay and had begun statin treatment within 90 days after discharge. Primary endpoint was the combined outcome of recurrent AMI or death from any cause.

A total of 18,637 patients were prescribed atorvastatin, pravastatin, simvastatin, lovastatin, or fluvastatin. Adjusted HRs (and 95% CI) for the combined outcome of AMI or death showed that each statin had similar effects when compared with atorvastatin: pravastatin, 1.00 (0.90-1.11); simvastatin, 1.01 (0.91-1.12), lovastatin, 1.09 (0.95-1.24), and fluvastatin, 1.01 (0.80-1.27). Results did not change when death alone was the endpoint, nor did they change after censoring of patients who switched or stopped the initial statin treatment.

"Statins used at their regular prescribed doses as found in the study appeared to be equivalent to reducing incidence of recurrent AMI or death in older patients who had a recent AMI," Dr. Zhou said. "Practice should be centered around the control of cholesterol, instead of the type of statin prescribed. Regular cholesterol check-ups according to guideline recommendations are necessary."

Source: CMAJ 2005; 172(9):1187-94.

COPYRIGHT 2005 Advanstar Communications, Inc.
COPYRIGHT 2005 Gale Group

Return to Fluvastatin
Home Contact Resources Exchange Links ebay